Dear Reader,
The war with Iran is making big news - distracting investors from opportunity in gold.
For example: one tiny Canadian gold miner is about to file Q1 earnings. When they do, the entire world of investors will see that its fair valuation is at least 5X higher than today’s stock price.
This kind of favorable set up for miners occurs rarely. Big miners have dozens of projects. A newly productive mine does not move the needle when it’s a small part of a bigger company.
But this company has one major project - and it just produced its first ounces of gold…
Get the ticker and full details here.
This company has over 1 million ounces of gold in the ground worth close to $5 billion. It’s currently selling for under $1 billion. The math is simple: at current pricing, buying it today is like buying a nickel for a penny.
But that won’t last.
The earnings report will be posted in mid-May. If you wait til then, it will be too late.
Get the full briefing on this pre-earnings gold stock.
Best,
Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio
P.S. This company also has plans to quadruple production in the coming months - another fact that will become obvious to the market AFTER the earnings report posts in May.
D-Wave Keeps Delivering Good News—So Why Is It Falling?
Author: Nathan Reiff. Posted: 3/11/2026.
Key Points
- D-Wave Quantum shares remain down about a third year-to-date despite numerous technological and business successes.
- The company's bookings and revenue have climbed rapidly alongside gross margin, but operating expenses are also climbing, keeping profitability distant for now.
- With a major new Fortune 100 client and other sales momentum, D-Wave may test investor patience while it works to bring its financials in line with its valuation.
- Special Report: Elon's "Hidden" Company
A longtime speculative play in the risky, emerging quantum computing industry, D-Wave Quantum Inc. (NYSE: QBTS) appears poised to separate true quantum bulls from investors who rode its 168% surge in 2025. Despite that rally, D-Wave shares have spent most of 2026 trading lower or flat; QBTS is down nearly a third year-to-date (YTD).
Some reasons for this pullback are obvious: the company missed analyst expectations on both earnings and revenue in the most recent quarter. At the same time, rivals like IonQ Inc. (NYSE: IONQ) may be quietly outperforming on some metrics.
A gold miner just beat every single member of the Magnificent 7 (Ad)
Newmont, the world's largest gold miner, doubled over the past year — beating Apple, Nvidia, Meta, Tesla, Amazon, and Google. And more than two dozen smaller names have done even better. JC Parets calls it the "Chaos Cycle," a 135-year-old pattern where overlooked real-asset stocks quietly deliver the biggest gains in decades.
He just recorded an urgent briefing on what's driving this shift — including one stock name he's giving away free.
Go here for JC's full briefingNonetheless, several positive developments D-Wave has highlighted in recent months might have helped reverse the slide.
Specifically, strong bookings growth, a high-profile new deal, and an expanded two-pronged technology approach have so far failed to steady the QBTS share price.
D-Wave's Rally, Cut Short in October, Waits for a Reason to Relaunch
To understand D-Wave's current position, it helps to backtrack to October 2025, when the selloff began. After reaching a high near $45 per share in mid-October, QBTS plunged to less than half that level before a modest recovery into year-end. There wasn't an obvious fundamental catalyst for the reversal; it may simply have been shareholders cashing out or concerns that the hype outpaced D-Wave's near-term achievements.
If that was the case, the rally could resume once D-Wave gives investors tangible reasons to be excited beyond general market enthusiasm. That hasn't happened yet, despite several financial wins, including more than $30 million in bookings so far in 2026, a 265% increase in gross profit for full-year 2025, and an impressive gross margin of nearly 83% last year.
Financials and Tech Potential May Still Be Mismatched
D-Wave's recent financial performance is notable, but two metrics may keep many investors skeptical about a $45-per-share valuation. First, revenue remains small—about $25 million in 2025—for a company with roughly a $7 billion market capitalization, even though revenue nearly tripled year-over-year. Second, operating expenses rose 46% in 2025 to roughly $121 million.
Revenue is growing faster than expenses, and strong bookings and high margins help the story, but there's still a significant gap between where D-Wave stands today and a quarter in which it breaks even or turns a profit. The valuation is also rich: a price/sales (P/S) ratio around 286.5 and a book value of roughly $2.30 per share raise questions about commercial viability, even after announcing a new agreement with a Fortune 100 company.
At the same time, D-Wave's technology potential remains compelling. Its dual-technology approach, enabled by this year's acquisition of Quantum Circuits, should help the company design and build quantum systems more efficiently and broaden its addressable market.
Wall Street Analysts Remain Bullish, But Retail Investors May Not Have the Patience
Wall Street remains optimistic: 14 of 16 analyst ratings are Buy or equivalent, and the consensus price target sits roughly 92% above current levels.
Retail investors, however, may be less willing to keep a speculative position in a company that could still be far from aligning its financials with its technological promise.
Conversely, investors who can tolerate volatility and believe D-Wave can grow revenue, rein in expenses, and further differentiate its quantum technology may find themselves early stakeholders in a potential industry leader.
That outcome is far from guaranteed, and the timeline for when—or if—those expectations are met remains uncertain.
The Real Reason Eli Lilly Is Pouring $3 Billion Into China
Reported by Jeffrey Neal Johnson. Article Published: 3/13/2026.
Key Points
- Eli Lilly is committing $3 billion over a decade to expand manufacturing in China, targeting a GLP-1 market that some analysts estimate could reach $14 billion by 2030.
- The investment is designed to close a manufacturing gap with Novo Nordisk while building cost advantages against more than 60 domestic Chinese competitors developing rival GLP-1 drugs.
- Local production also hedges against supply chain risks tied to trade friction, a vulnerability that recent global GLP-1 shortages have already exposed.
- Special Report: Elon's "Hidden" Company
Eli Lilly and Company (NYSE: LLY) is a titan of the pharmaceutical industry, a position reinforced by the success of its GLP-1 diabetes and obesity drug franchise. With products like Mounjaro and Zepbound transforming patient care and generating blockbuster sales, Lilly's stock price has climbed to the top of the S&P 500.
In a move that signals long-term ambition, Lilly has announced a $3 billion, decade-long plan to expand manufacturing in China. That prompts a key question for shareholders: why invest so heavily in China now? The answer demonstrates strategic foresight and outlines a clear blueprint for Lilly's next phase of growth.
Why China? An Unprecedented Market Opportunity
A gold miner just beat every single member of the Magnificent 7 (Ad)
Newmont, the world's largest gold miner, doubled over the past year — beating Apple, Nvidia, Meta, Tesla, Amazon, and Google. And more than two dozen smaller names have done even better. JC Parets calls it the "Chaos Cycle," a 135-year-old pattern where overlooked real-asset stocks quietly deliver the biggest gains in decades.
He just recorded an urgent briefing on what's driving this shift — including one stock name he's giving away free.
Go here for JC's full briefingTo understand Lilly's strategy, investors must first appreciate the scale of the opportunity. China faces a significant public health challenge: an estimated 141 million people living with diabetes and more than 600 million adults who are overweight or obese. As the middle class grows and healthcare spending rises, demand for effective treatments is set to accelerate.
That creates a vast and still largely untapped pool of potential patients for Lilly's leading medications. Market forecasts project China's GLP-1 market to expand rapidly, with some analysts estimating it could reach roughly $14 billion by 2030. This growth makes China a critical long-term engine for Lilly's flagship injectable products and for its next wave of innovation, including the oral drug orforglipron. For a daily oral medication to succeed at scale, efficient, high-volume local manufacturing is not just an advantage—it is a necessity. Securing local capacity is essential to maintaining global leadership.
Lilly's Great Wall: A Strategy for Supply and Supremacy
Eli Lilly's investment serves a dual purpose: it builds a defensive shield against external risks while creating an offensive advantage to capture market share. This proactive approach should reassure investors about management's ability to navigate a complex global landscape and protect future earnings.
The Geopolitical Shield
First, the move strengthens supply-chain resilience. The U.S. pharmaceutical industry relies heavily on China for Active Pharmaceutical Ingredients (APIs), and that dependence is a significant vulnerability amid rising trade friction. By establishing a robust presence in China, Lilly reduces its exposure to potential export controls or logistics disruptions. Lessons from recent global GLP-1 shortages make clear that local manufacturing helps ensure a stable supply of medicines to Chinese patients, builds brand loyalty, and provides shareholders with revenue streams that are less susceptible to geopolitical volatility.
The Competitive Weapon
Second, the investment is an offensive tool in a fiercely competitive market. Lilly faces a two-front challenge in China. Its main global rival, Novo Nordisk (NYSE: NVO), already has an established manufacturing footprint there, so Lilly's expansion is necessary to level the playing field on supply, speed, and scale.
Equally important is the rise of local competition: more than 60 Chinese pharmaceutical companies are developing GLP-1 candidates, which will put downward pressure on prices over time. By manufacturing locally and partnering with domestic specialists like Pharmaron, Lilly can achieve greater cost efficiencies and pricing flexibility. That positions the company to defend market share against lower-cost alternatives, protect long-term margins, and build a more durable competitive moat.
Why This Move Secures Future Returns
This multi-billion-dollar strategy reinforces the bullish investment case for Eli Lilly. It's not just about growing sales; it's about creating a durable, defensible, and highly profitable global business. Capturing a meaningful share of China's GLP-1 market could add billions in annual revenue, providing a long runway for growth that supports Lilly's premium valuation.
Wall Street sentiment remains positive. The analyst consensus for Lilly's stock is a Moderate Buy, with an average price target near $1,230. That optimism rests on the current success of Mounjaro and Zepbound and on confidence that management will continue making strategic investments to secure future growth. The China commitment is a tangible validation of that strategy.
By establishing a powerful third pillar of global growth alongside the U.S. and Europe, Lilly is diversifying and strengthening its overall business. For investors, the $3 billion commitment is not a gamble but a calculated foundation for the company's next decade of expansion, reinforcing Eli Lilly's standing as a global pharmaceutical leader and making a compelling case for long-term value.
to bring you the latest market-moving news.
This email message is a sponsored email provided by Golden Portfolio, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 North Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. United States..
0 Response to "A 5X gold stock no one's watching yet"
Post a Comment